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Endothelial dysfunction is one of the main characteristics of chronic hypertension and it is characterized by impaired nitric oxide
(NO) bioactivity determined by increased levels of reactive oxygen species. Endothelial function is usually evaluated by measuring
the vasodilation induced by the local NO production stimulated by external mechanical or pharmacological agent. These vascular
reactivity tests may be carried out in diﬀerent models of experimental hypertension such as NO-deﬁcient rats, spontaneously
hypertensive rats, salt-sensitive rats, and many others. Wire myograph and pressurized myograph are the principal methods used
forvascularstudies.Usually,increasingconcentrationsofthevasodilatoracetylcholineareaddedincumulativemannertoperform
endothelium-dependent concentration-response curves. Analysis of vascular mechanics is relevant to identify arterial stiﬀness.
Both endothelial dysfunction and vascular stiﬀness have been shown to be associated with increased cardiovascular risk.
1.Introduction
Hypertensioncontributessigniﬁcantlytoglobalcardiovascu-
larmorbidity andmortality. Itappearstohaveamultifaceted
connection with endothelial dysfunction that arises before
thedevelopmentofadversecardiovascularevents[1].Hyper-
tension is associated with endothelial dysfunction in the
peripheral, coronary, and renal circulations in the majority
of studies, indicating an important mechanism whereby hy-
pertensionpromotesthedevelopmentofvasculardisease[1–
4].
The endothelium is currently recognized to be essential
for the regulation of the vascular tone and structure [5].
Functional and structural vascular changes can develop in
the presence of cardiovascular risk factors, enhancing the
process of atherosclerosis. In this situation, there is a im-
balance between endothelium-derived nitric oxide (NO) and
other vasoprotective factors. Moreover, an excessive pro-
duction of proinﬂammatory and vasoconstrictors substances
such as angiotensin II, endothelin 1 (ET-1), and reactive oxy-
genspecies(ROS)maycontributetoimpairmentofendothe-
lial function, increasing the peripheral vascular resistance
which contributes to blood pressure raise and cardiovascular
remodeling [6]. In fact, endothelial dysfunction is one of
the main characteristics of chronic hypertension, and it is
characterized by impaired NO bioactivity determined by
increased levels of ROS [7]. Other systems contribute to this
imbalance such as renin-angiotensin and ET-1 which may
participate in the pathogenesis of endothelial dysfunction.
Indeed, ET-1 activity is increased along with reduced bioa-
vailability of NO [8].
Endothelial dysfunction is not speciﬁc to primary hyper-
tension since it may be associated with other risk factors
and cardiovascular diseases. Furthermore, there is no cor-
relation between the severity of endothelial dysfunction and
blood pressure levels. These two considerations indicate that
blood pressure raise is not determined by impairment of
endothelial function. On the other side, it has been reported
that an impaired response to acetylcholine correlates with
carotid intima-media thickening in patients with essential
hypertension [9]. The presence of coronary endothelial dys-
function has also been associated with cardiovascular events
in longitudinal studies [10]. Therefore, further studies are2 International Journal of Hypertension
required to ascertain a direct relationship between endothe-
lial dysfunction and cardiovascular events in patients with
essential hypertension.
2. Vascular Changes Inducedby Hypertension
Primary hypertension is characterized by an increase in pe-
ripheral vascular resistance. In animal models of hyper-
tension small arteries (lumen diameter between 100 and
400μm)developlesionsinducedbyhypertension,andcanbe
subjected to ex vivo studies [11]. The main determinant of
an increase in peripheral vascular resistance is the reduction
in lumen diameter. According to Poiseuille’s law, resistance
varies inversely with the fourth power of the blood vessel
radius. As a consequence,smallreductions in vascularlumen
increase arterial resistance into a considerable extent [12].
Threeimportantvascularcomponentsareaﬀectedbyhy-
pertension: vascular structure, vascular mechanics (stiﬀ-
ness), and vascular function [13]. Structural modiﬁcations
involve the reduction of lumen diameter and the thickening
of the vascular media, causing an increase in the media/
lumen ratio. The increase in media/lumen ratio can result
from a reduction of external diameter, causing a narrowing
ofthelumenwithoutanincreaseintotaldiameter(eutrophic
remodelling) or can occur due to media thickening (hyper-
t r o p h i cr e m o d e l i n g )[ 14].
Hypertension can also determine modiﬁcations in the
mechanical properties of an artery, promoting an increase
in vascular stiﬀness. These modiﬁcations can involve the ex-
pression and localization of extracellular matrix compo-
nents, such as collagen and integrins [15]. The hyperactivity
of the renin-angiotensin system is the main trigger for these
alterations. In addition, it has been previously demonstrated
that angiotensin II-induced vascular changes were at least
partially prevented by aldosterone antagonism, indicating
thatsome vascularactions of angiotensin II may be mediated
by aldosterone [16]. On the other hand, functional im-
pairment reﬂects a reduction in vasodilation induced by
nitric oxide, also called endothelium-dependent response,
measured by the acetylcholine response curve [17].
3.Pathophysiology ofEndothelial Dysfunction
NO is one of the most important vasodilating substances
released by the endothelium, acting as a vasodilator and in-
hibiting growth and inﬂammation. Impaired endothelial
functionhasbeendirectlyassociatedwithdecreasedbioavail-
ability of NO which can be originated mainly from oxidative
stress and inﬂammation [18]. In fact, C-reactive protein has
been shown to diminish endothelial NO synthase (eNOS)
[19], the enzyme that produces NO using L-arginine as sub-
strate. Moreover, both processes are connected since reactive
oxygen species (ROS) are able to upregulate intercellular
adhesion molecule1 (ICAM-1), vascular adhesion molecule1
(VCAM-1), and macrophage chemoattractant peptide1
(MCP-1)[20].Inhumanhypertensionandinanimalmodels
of hypertension, NAD(P)H oxidase has been demonstrated
to be the main source for oxidative excess, although other
sources, such as xanthine oxidase and mitochondria, have
also been described [21, 22]. In experimental models of
hypertension with hyperactivity of renin-angiotensin sys-
tem, such as angiotensin II-infused rats, increased ROS
are stimulated by NAD(P)H oxidase, resulting in vascular
inﬂammation [23]. Animal models of hyperhomocysteine-
mia have been associated with endothelial dysfunction even
with no elevation of blood pressure [24]. Mild hyperho-
mocysteinemia has also been linked to stiﬀer small arteries
with increased collagen deposition in the vascular wall.
These alterations may be stressed by angiotensin II-induced
hypertension [25]. This ﬁnding may explain the increased
cardiovascular risk linked to hyperhomocysteinemia.
It is well known that NO is a volatile substance, with a
very short half-life. Therefore, its bioavailability is usually
evaluated by measuring the vasodilation induced by the local
NO production stimulated by speciﬁc external mechanical
and pharmacological agent, that is, through vascular reactiv-
ity tests [26].
4. Relationship between
Macro- andMicrocirculation
The main purpose of large arteries is to transport a satis-
factory blood supply from the heart to peripheral tissues. In
additiontoconduitfunction,largearterieshaveacushioning
function that consists to transform the pulsatile ﬂow of arte-
rial vessels into the steady ﬂow required for oxygen supply.
Interactions between macro- and microvascular changes
seem to contribute to end-organ damage in hypertension.
The properties of conduit arteries are aﬀected by hyper-
tension resulting in reduced arterial compliance and dis-
tensibility. At the microvascular level, hypertensive disease
is characterized by eutrophic or hypertrophic remodeling
and capillary rarefaction [27]. Central pulse pressure may be
transmitted to microcirculation in circumstances where the
autoregulatory mechanisms normally protecting vital organs
are oﬀset. In fact, a microvascular disease is commonly
observed in association with end-organ damage [28].
After ventricular ejection, blood pressure propagates
along the arterial tree as a wave. Mainly at arteriolar branch-
ing, this wave may be reﬂected and then becomes retrograde.
In young individuals, the wave summation takes place in
early diastole, thus improving the diastolic coronary per-
fusion without disturbing cardiac afterload. A stiﬀer aorta
implicates in greater pulse wave velocity, causing the reﬂec-
tions to occur in late systole rather than in diastole as in
healthy subjects. Under this condition, coronary perfusion is
impaired, leading to myocardial ischemia [29].
It has been hypothesized that increased arterial stiﬀness
of the large arteries may lead to microvascular changes due
to increased pulsatile ﬂow. Pulse pressure and mean arterial
pressure (MAP) have been considered risk factors for car-
diovascular disease. MAP is the steady component of the
blood pressure curve and it is determined by cardiac output
and microvascular resistance. On the other hand, pulse
pressure is the pulsatile component that is determined by left
ventricular ejection, the compliance of the large arteries, andInternational Journal of Hypertension 3
the intensity of wave reﬂections from the microcirculation
[30].
The relationship between endothelial function and vas-
cular stiﬀness is still controversial. Witte et al. showed that
forearm ﬂow-mediated dilation (FMD) responses were af-
fected by arterial stiﬀness [31]. In addition, Parvathaneni
et al. showed a linear correlation between FMD responses
and both small and large arterial stiﬀness [32]. On the other
hand, neither large nor small arterial stiﬀness was considered
viableindicatorsofendothelialormicrocirculatoryreactivity
in healthy young males [33].
5.PrincipalModelsof
ExperimentalHypertension
Chronic inhibition of NO synthase by NG-nitro-L-arginine
methyl ester (L-NAME) in adult rats produces endothelial
dysfunction with increase of vascular responsiveness to
adrenergicstimuliassociatedwithperivascularinﬂammation
[27].Vascularremodeling,renin-angiotensinsystem,sympa-
theticnervoussystem,andendothelium-derivedconstricting
factors (EDCF) also play a role in L-NAME-induced hyper-
tension [28, 29]. Obviously, reduced NO synthesis is the
main mechanism for the blood pressure elevation induced
by L-NAME. Interestingly, continuation of L-NAME admin-
istration from 4 to 8 weeks further increases blood pres-
sure, but not enhancing the impairment of endothelium-
dependentrelaxation.Ithasbeenrecentlyreportedthat,after
4 weeks of L-NAME treatment, endothelial NO synthase
(eNOS) expression in the heart was signiﬁcantly increased
and this increase was ampliﬁed after 7 weeks of treat-
ment [30]. This ﬁnding suggests that the upregulation of
eNOS protein expression represents one of counterregula-
tory mechanisms activated to compensate the blood pressure
raise. Impairment of NO signaling has been improved after
the cessation of L-NAME administration. However, persist-
ingarterialstructuralalterationsandenhancedEDCFforma-
tion may decelerate blood pressure reduction even after the
restoration of NO synthase activity [29].
Spontaneously hypertensive rats (SHR) seem to be the
experimental model most similar to the human primary
hypertension. The involvement of NO for blood pres-
sure elevation in these animals is still controversial. Notably,
endothelium-dependent dilation is preserved in the prehy-
pertensive and early hypertensive stages of SHR [31]. More-
over, impaired endothelium-dependent relaxation was not
found in rats with borderline hypertension. This has been
supportedbytheﬁndingthattheiraorticNOproductionwas
even elevated in comparison with normotensive rats [32].
The increased sympathetic activity contributes to endo-
thelial dysfunction and blood pressure elevation in SHR. It
has been shown that NO counterbalances angiotensin II
eﬀects on sympathetic stimulation [33]. It has been recently
demonstrated that inhibition of angiotensin converting
enzyme lowers blood pressure in SHR by attenuating sym-
pathetic tone [34].
The cause for impairment of endothelial function in hy-
pertension is not completely elucidated. When compar-
ing SHR with NO-deﬁcient rats, it has been shown that
alterations in the vascular wall in both groups of animals
but the endothelium-dependent dilation in aorta is clearly
reduced in NO-deﬁcient rats while relatively preserved in
SHR[35].Thisﬁndingindicatesthatendothelialdysfunction
in hypertension is not related to vascular structural changes.
In salt-dependent hypertension, the reduction of NO
bioavailability caused by increased ROS levels seems to play
a signiﬁcant role in the pathogenesis of blood pressure eleva-
tion and endothelial dysfunction [36]. Renal hemodynamics
may be changed by local oxidative stress resulting in sodium
retention [37]. Particularly, renin-angiotensin system does
not contribute to hypertension in this experimental model.
On the other hand, sympathetic hyperactivity has been
shown in salt-hypertensive Dahl rats leading to vasoconstric-
tion which becomes superior to NO-dependent vasodilation
[38].
6.VascularReactivityby WireMyograph
In some experimental studies, an artery can be dissected,
immediately immersed in cold physiological salt solution
(PSS), and cleaned of adipose or connective tissue to be
mountedasring-shapedpreparationsinthesmallvesselwire
myograph.Two40μmstainlesssteelwiresarepassedthrough
the lumen of the vessel, and mounted in the jaws of the
wire myograph. After 30 min equilibration in oxygenated
(5% CO2, 95% O2 mixture) PSS, a standardized computer-
assisted normalization procedure is performed to set the pre-
tension of the arteries. This deﬁnes the lumen diameter that
the artery would have had in vivo when relaxed and under
at r a n s m u r a lp r e s s u r eo f1 0 0m m H g .T h ea r t e r i e sw e r et h e n
set to the lumen diameter of 90% of the normalized inner
diameter when active force development was maximal [39].
Before the start of measurements, the vessels are allowed
to stabilize in PSS for 30 minutes. After preconstriction
with noradrenaline addition, the arterial contraction reaches
a steady state. Thus, increasing concentrations of the va-
sodilator acetylcholine are added in cumulative manner
to perform endothelium-dependent concentration-response
curves [40]. There are many agents, such as histamine, brad-
ykinin,ATP,andserotonin,whichproducearterialrelaxation
either by direct action on the smooth muscle cell or by
indirect action mediated by activation of endothelial recep-
tors. However, acetylcholine is the more commonly used
substance to activate endothelial receptors in this setting.
7.VascularStudiesUsing
Pressurized Myography
7.1. Preparing Vessels for Functional Studies. A technique that
provides important information about structural, mechani-
cal, and functional properties in small vessels is the pressur-
ized myography (Figure 1). This method oﬀers advantages
for the analysis of structural features compared to conven-
tional histology techniques, because it observes the vessel in
ex vivo preparation, without the artefacts induced by tissue
ﬁxation [41]. In the pressurized myograph, the vessel is4 International Journal of Hypertension
3rd branch
45 mmHg
Figure 1: The third branch of mesenteric vessels to be dissected
and mounted in a pressurized myograph in rat studies. The vessel
is attached to micropipettes, connected to transducers keeping
45mmHg as a ﬁxed intraluminal pressure for functional studies.
dissected and cannulated in both ends with micropippetes
that are connected to intraluminal pressure transducers,
allowing pressure control. The perfusion chamber where the
vessel is immersed is supplied with a perfusion system that
keeps changing a physiological solution continuously. This
allowstheinfusionofpharmaceuticalswithdiﬀerentconcen-
trations for the evaluation of vascular diameter, indicating
its functional properties. The vessel image is obtained with
t h ea i do fo p t i cm i c r o s c o p y ,r e c o r d e db yav i d e oc a m e r a
and exposed in a video monitor. This image is analysed for
the determination of wall thickness and vascular diameter
[42, 43].
7.2. Evaluation of Structural Changes. From data obtained
with the pressurized myograph, we can gather information
about arterial structure, employing formulas that take into
account the cylindrical geometry of the vessel [44]. As a
result, when we apply to the vessel a constant intraluminal
pressure of 45mmHg, the media cross-sectional area (CSA)
is obtained subtracting the external from the internal vascu-
lar transversal area:
CSA =

π
4

D2
e − D2
i

,( 1 )
where De and Di are the external and internal diameters,
respectively.Itisalsopossibletoadjustintraluminalpressure,
in order to observe the variations in the external diameter of
the vessel, which correspond to the extent of vascular stiﬀ-
ness.
7.3. Vascular Mechanics. In vascular mechanics evaluation,
resistance arteries must be previously deactivated by extra-
luminal perfusion with calcium-free PSS for 30min in order
toeliminateanymyogenictone.Intraluminalpressureisthen
increasedto140mmHgthreetimes,andthecannulamustbe
adjusteduntilthearterywallsarestraightandparalleltoeach
other. A servo-controlled pump is used to increase intralu-
minal pressure in increments of 10mmHg until a pressure
of 40mmHg is achieved, and then in 20mmHg increments
until a pressure of 140mmHg is reached. Media thickness
and lumen diameter must be assessed at each pressure level
at diﬀerent points along the vessel, and the average is used
in subsequent calculations. The initial diameter is measured
at 3mmHg unless the vessel collapses. In these cases, lumen
diameter has to be estimated by ﬁtting the intraluminal
pressure-lumen diameter data with a third-order polynomial
equation. The incremental distensibility is the percentage of
change in lumen diameter (ΔD/D)f o rag i v e nc h a n g ei n
intraluminal pressure (ΔP):
Incremental distensibility =

1
ΔP

×

ΔD
D

×100. (2)
Circunferencial strain (ε) is calculated as ε = (D − D0)/
D0,w h e r eD is the lumen diameter observed in a given intra-
luminalpressureandD0 correspondstotheoriginaldiameter
or estimated with intraluminal pressure of 3mmHg. The cir-
cumferential stress (σ) is calculated as σ = (PD)/2M,w h e r e
P is intraluminal pressure, D and M are luminal diameter
and media thickness, respectively. Pressure is converted from
mmHg to dyn/cm2 (1mmHg = 1,334 × 103 dyn/cm2).
8. Conclusions
In conclusion, although not speciﬁc to hypertension, en-
dothelial dysfunction frequently develops in hypertensive
animals. The reduction of NO bioavailability caused by in-
creased ROS is the main mechanism involved in the patho-
genesis of endothelial dysfunction. Nevertheless, hyperac-
tivity of renin-angiotensin system, endothelin, sympathetic
activation, and inﬂammation may also contribute to oxida-
tive stress and endothelial dysfunction. The participation of
these systems may vary in diﬀerent animal models of hyper-
tension. Wire myograph and pressurized myograph are the
key methods for vascular evaluation in the experimental
setting. Along with endothelial function evaluation, analysis
of vascular mechanics is relevant to identify arterial stiﬀness
which appears to be associated with cardiovascular events.
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